UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 21, 2009
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-31191
|
|
04-3324394 |
|
|
|
|
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer |
of Incorporation)
|
|
File Number)
|
|
Identification No.) |
|
|
|
8 Sylvan Way |
|
|
Parsippany, New Jersey
|
|
07054 |
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (973) 290-6000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers
T. Scott Johnson resigned as a director of The Medicines Company (the Company) effective July 21,
2009. Dr. Johnson resigned from the board of directors to devote his efforts to his new full-time
role as Vice President, New Business Ventures & Chief Medical Advisor of the Company. On July23,
2009, the Company issued a press release regarding Dr. Johnson, a copy of which is attached hereto
as Exhibit 99.1.
Dr. Johnson had also served as a member of the Companys Audit Committee prior to his commencement
of employment with the Company. The Companys board of directors appointed William Crouse, a
current member of the board of directors, to fill the vacancy on the Audit Committee created by Dr.
Johnsons departure.
Item 9.01. Financial Statements and Exhibits
(c) Exhibits
|
|
|
99.1 |
|
Press release dated July 23, 2009 entitled The Medicines Company
Appoints T. Scott Johnson as Vice President, New Business Ventures & Chief
Medical Advisor |